This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Vapotherm Valuation

Is VAPO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VAPO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VAPO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VAPO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VAPO?

Key metric: As VAPO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VAPO. This is calculated by dividing VAPO's market cap by their current revenue.
What is VAPO's PS Ratio?
PS Ratio0.2x
SalesUS$70.92m
Market CapUS$13.61m

Price to Sales Ratio vs Peers

How does VAPO's PS Ratio compare to its peers?

The above table shows the PS ratio for VAPO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
TRIB Trinity Biotech
0.2x11.8%US$10.7m
NURO NeuroMetrix
2.3xn/aUS$8.6m
SCND Scientific Industries
1.1xn/aUS$10.7m
HLTH Cue Health
0.2x38.4%US$14.7m
VAPO Vapotherm
0.2xn/aUS$13.6m

Price-To-Sales vs Peers: VAPO is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.8x).


Price to Sales Ratio vs Industry

How does VAPO's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.3x8.2%
VAPO Vapotherm
0.2xn/aUS$13.61m
INGN Inogen
0.7x4.2%US$232.94m
ARAY Accuray
0.4x5.5%US$204.15m
VAPO 0.2xIndustry Avg. 3.3xNo. of Companies50PS03.26.49.612.816+
50 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.3x17.1%
VAPO Vapotherm
0.2xn/aUS$13.61m
No more companies

Price-To-Sales vs Industry: VAPO is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Medical Equipment industry average (3.3x).


Price to Sales Ratio vs Fair Ratio

What is VAPO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VAPO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VAPO's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies